Biotechnology company focused on licensing and developing therapeutic antibodies.
XOMA Corporation functions as a biotechnology royalty aggregator with a global presence spanning Europe, the United States, and the Asia Pacific. The company plays a pivotal role in advancing human health by partnering with biotech firms to acquire future economic interests linked to pre-commercial therapeutic candidates licensed to pharmaceutical and biotechnology companies. Specifically targeting early to mid-stage clinical assets, often in Phase 1 and 2 trials, XOMA focuses on opportunities with potential for commercial sales through strategic partnerships.
With a robust portfolio comprising approximately 70 assets, XOMA Corporation leverages its expertise to identify and acquire promising therapeutic candidates poised for development and eventual commercialization. This approach underscores the company's commitment to fostering innovation in biotechnology and enhancing patient outcomes globally.
Established in 1981 and headquartered in Emeryville, California, XOMA Corporation has cultivated a reputation for its strategic investments and partnerships within the biopharmaceutical industry. By securing future economic benefits from a diverse range of clinical assets, the company continues to drive growth and value creation while contributing to advancements in medical science.
Through its comprehensive approach and long-standing presence in the biotechnology sector, XOMA Corporation remains dedicated to supporting the development of breakthrough therapies that address unmet medical needs and improve the quality of life for patients worldwide.